Schrodinger receives $57M cash from Eli Lilly's Ajax acquisition, boosting liquidity
SDGR sits 59% above its 52-week low of $10.945.
Summary
Schrodinger has received a $57 million cash payment following Eli Lilly's acquisition of Ajax Therapeutics. This payment stems from Schrodinger's co-founding role and stake in Ajax, an event that was initially highlighted in the company's Q1 report and related news in early May. The cash inflow, confirmed by an 8-K filed today, significantly enhances Schrodinger's liquidity and validates its drug discovery platform. The company remains eligible for additional milestone payments related to Ajax's clinical and regulatory progress.
At the time of this announcement, SDGR was trading at $17.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $10.95 to $23.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.